SEC Form 4 · accession 0000899243-16-019674
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roger Louis
Officer — Chief Compliance Officer
Period of report
May 9, 2016
Accepted (ET)
May 11, 2016 · 4:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $2.46 | May 9, 2016 | A | 17,000 | A | — | May 9, 2026 | Common Stock | 17,000 | 17,000 | D |
| Restricted Stock UnitsF3,F4 | — | May 9, 2016 | A | 8,000 | A | — | — | Common Stock | 8,000 | 8,000 | D |
Explanation of responses
- F1The stock option award has an exercise price equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant.
- F225% of the shares of common stock underlying this stock option award will vest on May 9, 2017. The remaining 75% of the shares of common stock underlying this stock option award will vest thereafter in equal monthly installments through May 9, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.
- F3Each restricted stock unit represents a contingent right to receive one share of common stock.
- F4The restricted stock units will vest in three annual installments, with 33.34% of the units vesting on May 9, 2017, 33.33% of the units vesting on May 9, 2018, and 33.33% of the units vesting on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.